Evaluated the Efficacy and Safety of APCP on Hair Health

Amorepacific

Status

Completed

Conditions

Hair Damage

Treatments

Dietary Supplement: APCP I

Dietary Supplement: APCP II

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06422026

AP-PV-2022-02

Details and patient eligibility

About

This study is designed to evaluate the efficacy and safety of APCP in promoting hair health in adult with mild to moderate hair damage, compared to a placebo control.

Enrollment

150 patients

Sex

All

Ages

19 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Glossy scores according to the visual evaluation classification method correspond to 1 point or more and 3 points or less and a total hair damage score of less than 18 points evaluated according to exposure to risk factors
A person capable of maintaining the same hair shape and color during this human body application test
A person who has agreed to participate in this human application test before the start of the human application test and filled out the Informed Consent Form

Exclusion criteria

A person currently being treated for infectious diseases and malignant tumors, including severe cardiovascular system, immune system, respiratory system, hepatometer, kidney and urology system, nervous system, musculoskeletal system, psychosis, skin, etc
As of Visit 1, those who currently have dull dermatitis, scalp psoriasis, and scalp infection
A person who plans to manage and operate hair supplies, hair products during this human body application test
A person who has taken oral Dutasteride or Finasteride within 6 months of visit 1
A person who has applied topical hair growth agents, wool, and hair growth agents for the last 1 month (30 days) or more as of Visit 1
Those who have been administered systemic steroids, cell death agents, vasodilators, antihypertensive agents, antiepileptic agents, beta receptor blockers, bronchodilators, diuretics, Cimetidine, Diazoxide, Cyclosporine, and Ketoconazole for the last 1 month or more (30 days)
A person who has applied topical steroids to the scalp for the last 1 month (30 days) or more as of Visit 1
A person who has participated in other interventional clinical trials (including human application tests) within one month (30 days) of visit 1 or plans to participate in other interventional clinical trials (including human application tests) after the start of this human application test
A person who is pregnant or who has a plan to become pregnant during the nursing mother or during this human body application test
A person who is sensitive to or allergic to food ingredients for this human body application test
A person who is deemed inappropriate by the tester for other reasons